AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock’s biggest one-day drop since 2020, after reports that it held merger talks with U.S. rival Bristol-Myers Squibb Company (NYSE:BMY). A combined company would be worth close to $400 billion, the fourth-largest drugmaker in the world by market value. Neither firm confirmed the talks, and people familiar with the matter told Reuters a deal may never materialize.
Why Investors Can’t Figure Out the Logic
Bristol Myers shares actually rose as much as 6% on the news before dropping back down a bit, a very different reaction from AstraZeneca’s shareholders. That split tells the real story: analysts and investors think Bristol-Myers Squibb Company (NYSE:BMY) needs this deal far more than AstraZeneca does. Jefferies analysts wrote they were “a bit perplexed” by the report, since AstraZeneca has built one of the strongest growth stories in pharma under CEO Pascal Soriot and doesn’t need clever money moves to hit its goals. One rationale given is AstraZeneca’s push into the U.S. market, where it completed a direct stock listing this year and already earns 42% of its sales.
This makes you wonder: is this really a smart move to lock in U.S. market access, or is Wall Street right that AstraZeneca is being asked to rescue a weaker rival for no good reason?
AstraZeneca’s Bull and Bear Case
AstraZeneca PLC (NYSE:AZN) targets $80 billion in annual revenue by 2030, up from $58.7 billion last year, and Soriot said just last week the company doesn’t “need M&A to deliver” on that goal. Its cancer drug pipeline is deep, and the firm has kept growing largely through its own research and licensing deals rather than big acquisitions.
However, the stock’s 9% drop shows investors hate the idea, and AstraZeneca’s own shareholders are the ones pushing back hardest. Union Investment’s Markus Manns said the deal “does not make strategic or financial sense,” and ATG Healthcare’s Lukas Leu called it growth-dilutive in the near term. The reaction comes just weeks after a separate late-stage trial failure already raised questions about management’s credibility.
Bristol Myers’s Bull and Bear Case
Bristol-Myers Squibb Company (NYSE:BMY) shares rose on the report, and the stock is already up by over 22% year to date as of July 31. A merger would pair the company with a partner (AstraZeneca) that has less patent-expiry pressure and a stronger pipeline, potentially creating the broadest oncology portfolio in the industry.
Still, the firm needs the deal for a reason investors don’t like: its two biggest products, blood thinner Eliquis and cancer drug Opdivo, both face patent expiration and generic competition in the coming years, and growth is expected to decline starting next year. BMO’s Evan Seigerman noted that heavy overlap between Bristol’s Opdivo and AstraZeneca’s Imfinzi “could reduce the odds of a successful merger” on antitrust grounds alone.
Insider Monkey’s Hedge Fund Data
Insider Monkey’s hedge fund database shows AstraZeneca PLC (NYSE:AZN) had 56 hedge fund holders as of Q1 2026, up from 52 the quarter before, with the dollar value of hedge funds held rising from about $4.21 billion to $5.50 billion. Bristol Myers had 83 holders, up slightly from 82. Among other large pharma names, Pfizer had 83 holders, and Merck had 98, down from 100. Bristol Myers and AstraZeneca both are behind Merck but sit close to Pfizer in popularity.
Conclusion
This deal talk has already cost AstraZeneca shareholders real money. The stock market’s message is clear, i.e., Bristol-Myers looks like the company that needs saving, and AstraZeneca’s investors don’t want to rescue them. Nonetheless, hedge funds are bullish on Bristol-Myers Squibb Company (NYSE:BMY) and favor it over AstraZeneca.
While we acknowledge the risk and potential of AZN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AZN and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: Hedge Funds Are Bullish on DXC Technology (DXC) and Honeywell Technologies (HON)’s First Earnings as a Standalone Company: Bull vs Bear Analysis.
Disclosure: None. This article is originally published at Insider Monkey.
Hedge Fund Resource Center